<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400645</url>
  </required_header>
  <id_info>
    <org_study_id>14-132</org_study_id>
    <nct_id>NCT02400645</nct_id>
  </id_info>
  <brief_title>TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain</brief_title>
  <acronym>LATAP</acronym>
  <official_title>Comparison of Laparoscopically Assisted Transversus Abdominis Plane Block Using Liposomal Bupivacaine With Pre-incisional Bupivacaine for Post-operative Pain Control in Patients Undergoing Laparoscopic or Robotic Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized, controlled, double-blinded trial we plan to evaluate post-operative pain
      relief after laparoscopic-assisted Transversus Abdominis Plane (TAP) block using liposomal
      bupivacaine plus bupivacaine versus pre-incisional would infiltration with bupivacaine in
      patients undergoing Total laparoscopic or robotic assisted laparoscopic hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing laparoscopic or robotic assisted total hysterectomy at Erlanger Hospital
      will be randomized into one of two groups to receive either laparoscopic assisted TAP block
      with liposomal bupivacaine and bupivacaine (Group A) or pre-incisional bupivacaine (Group B).
      The remaining aspects of the perioperative care, including the general anesthesia care and
      postoperative care will be similar for all patients. Ideally, patients will be informed and
      consented for the study in the preoperative clinic setting. They will be randomized in the
      pre-anesthesia care unit.

      Patients in Group A will receive laparoscopic-assisted bilateral TAP blocks using 10cc
      liposomal bupivacaine, 10cc Bupivacaine 0.25% and 10cc Normal Saline one each side. Patients
      in Group B will receive a total of 20cc pre-incisional Bupivacaine divided between each of
      the trocar sites. All patients will receive Ketorolac 30 mg, IV at the conclusion of surgery.
      All patients will be offered either oral pain medications or patient controlled anesthesia
      (PCA) opiate pain medication as indicated. Morphine equivalents will be calculated.

      Postoperative pain control will be assessed using Visual Analog Pain Score (VAS). This will
      be done by recovery room personnel who will be blinded as to whether the patients received
      TAP block or pre-incisional anesthetic. VAS will be assessed at rest at 1 hour and 2 hours
      after arrival to PACU. Patients will be assessed with Overall Benefit of Anesthesia Score
      (OBAS) questionnaires at postoperative days 1, 2 and 7. OBAS questionnaires will be done by
      personnel blinded to anesthesia technique. Patients will also be blinded as to which group
      they were in. Total morphine equivalents of intraoperative and postoperative pain medications
      will be calculated through postoperative day 7.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It was determined that one member of the team had falsified data.
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog pain scores (VAS)</measure>
    <time_frame>Two hours</time_frame>
    <description>Postoperative pain at 1 hour and 2 hours after arrival to recovery using Visual Analog Pain Scores (VAS)
VAS: 0 (no pain) TO 10 (worst possible pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Narcotic pain medication usage</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Narcotic pain medication usage intraoperative and in recovery assessed as morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic pain medication following surgery</measure>
    <time_frame>1 week</time_frame>
    <description>Narcotic pain medication pill counts up to one week postoperatively</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Benefit of Anesthesia scores (OBAS) on postoperative days 1,2 and 7</measure>
    <time_frame>One week</time_frame>
    <description>Overall Benefit of Anesthesia Scores (OBAS) Questionnaires at postoperative days 1,2 and 7.
OBAS covers pain, vomiting, itching, sweating, freezing, dizziness and overall satisfaction on a scale of 0 to 10.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group A: pre-incisional bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: laparoscope to place TAP block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pre-incisional wound infiltration</intervention_name>
    <description>Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions</description>
    <arm_group_label>Group A: pre-incisional bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscope to place TAP block with liposomal bupivacaine</intervention_name>
    <description>Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%</description>
    <arm_group_label>Group B: laparoscope to place TAP block</arm_group_label>
    <other_name>Laparoscopic TAP block with Liposomal bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Use of Liposomal bupivacaine in laparoscopic TAP block</description>
    <arm_group_label>Group B: laparoscope to place TAP block</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.</description>
    <arm_group_label>Group A: pre-incisional bupivacaine</arm_group_label>
    <arm_group_label>Group B: laparoscope to place TAP block</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.</description>
    <arm_group_label>Group A: pre-incisional bupivacaine</arm_group_label>
    <arm_group_label>Group B: laparoscope to place TAP block</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status 1-3,

          -  Scheduled for laparoscopic or robotic assisted laparoscopic hysterectomy,

          -  Able to participate personally or by legal representation in informed consent

        Exclusion Criteria:

          -  History of relevant allergy to the study drugs (Bupivacaine),

          -  Chronic opioid use or drug abuse history,

          -  Inability to understand the study protocol,

          -  Refusal to provide written consent,

          -  Soft tissue infection of the abdominal wall and skin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shanti I Mohling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>laparoscopic hysterectomy</keyword>
  <keyword>robotic assisted hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

